Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma

Rakesh Popat¹, Selina J Chavda²

Affiliations

¹ University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK; Cancer Institute, University College London, London, UK. Electronic address: rakesh.popat@ucl.ac.uk.
² University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK; Cancer Institute, University College London, London, UK.

PMID: 37793762
DOI: 10.1016/S2352-3026(23)00244-2

Comment

Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma

Rakesh Popat et al. Lancet Haematol. 2023 Oct.

. 2023 Oct;10(10):e788-e789.

doi: 10.1016/S2352-3026(23)00244-2.

Authors

Rakesh Popat¹, Selina J Chavda²

Affiliations

¹ University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK; Cancer Institute, University College London, London, UK. Electronic address: rakesh.popat@ucl.ac.uk.
² University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK; Cancer Institute, University College London, London, UK.

PMID: 37793762
DOI: 10.1016/S2352-3026(23)00244-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

RP has received grants from GSK, paid to the University of Leeds, UK; consulting fees from Janssen, GSK, and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Bristol Myers Squibb, Sanofi, GSK, and Pfizer; and funds for travel or attendance at meetings from Janssen and GSK. SJC declares no competing interests.

Comment on

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Voorhees PM, et al. Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11. Lancet Haematol. 2023. PMID: 37708911 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma

Affiliations

Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical